<DOC>
	<DOC>NCT02400866</DOC>
	<brief_summary>This aim of study is to evaluate the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy by a randomized, double-blind, placebo-controlled trial.</brief_summary>
	<brief_title>A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Olanzapine</mesh_term>
	<criteria>over 19 years of age no history of receiving moderately or highly emetogenic chemotherapy during last 6 months, and is to receive a first course of MEC including one or more of following agents: Carboplatin, Cyclophosphamide ≤ 1,500 mg/m2, Daunorubicin, Doxorubicin &lt; 60 mg/m2, Epirubicin ≤ 90 mg/m2, Irinotecan, Oxaliplatin, Melphalan, Methotrexate ≥ 250 mg/m2 ECOG performance status 02 predicted life expectancy ≥ 3 months adequate bone marrow, kidney, and liver functionas evidenced by: ANC ≥ 1,500/mm3, platelet count ≥ 100,000/mm3, total bilirubine ≤ 2 x ULN, AST ≤ 3 x ULN, ALT ≤ 3 x ULN (for subjects with known liver metastases, total bilirubin ≤ 3 x ULN, AST ≤ 5 x ULN, ALT ≤ 5 x ULN), Creatinine ≤ 1.5 x ULN or Ccr ≥ 50 ml/min no episodes of nausea and vomiting during last 24 hours before enrollment subjects provides written informed consent Exclusion criteria: subjects with uncontrolled neuropsychiatric disease (alcohol abuse, seizure, psychosis etc) except malignant tumor subject is scheduled to receive highly emetogenic chemotherapeutic agents: Doxorubicin or Epirubicin + cyclophosphamide, Cisplatin ≥ 50 mg/m2, Carmustine &gt; 250 mg/m2, Cisplatin ≥ 50 mg/m2, Cyclophosphamide &gt; 1,500 mg/m2, Dacarbazine, Doxurubicine ≥ 60 mg/m2, Epirubicine &gt; 90 mg/m2, Ifosfamide ≥ 2 g/m2 per dose, Mechlorethamine, Streptozocin contraindication to the administration of palonosetron, dexamethasone, and olanzapine due to hypersensitivity or any other reasons subject has severe cognitive impairment subjects has symptomatic or uncontrolled brain metastasis or brain tumor female subjects of childbearing potential who dose not agree to use a proper contraceptive methods or to limit breast feeding subject has taken the following agents: risperidone, quetiapine, clozapine, phenothiazine, butyrophenone, 5HT3 antagonist, bezamides, domperidone, cannabinoids, NK1 antagonist, bezodiazepines subject has a plan to receive other chemotherapy, abdomial radiation, surgery, or immunotherapy any history of arrhythmia, uncontrolled congestive heart failure, acute myocardial infarction durting last 6 months history of uncontrolled diabetes subject who has used any investigational drugs within 30 days of randomization</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>cancer patients receiving moderately emetogenic chemotherapy</keyword>
</DOC>